Literature DB >> 22131303

The monocarboxylate transporter family--Structure and functional characterization.

Andrew P Halestrap1.   

Abstract

Monocarboxylate transporters (MCTs) catalyze the proton-linked transport of monocarboxylates such as L-lactate, pyruvate, and the ketone bodies across the plasma membrane. There are four isoforms, MCTs 1-4, which are known to perform this function in mammals, each with distinct substrate and inhibitor affinities. They are part of the larger SLC16 family of solute carriers, also known as the MCT family, which has 14 members in total, all sharing conserved sequence motifs. The family includes a high-affinity thyroid hormone transporter (MCT8), an aromatic amino acid transporter (T-type amino acid transporter 1/MCT10), and eight orphan members yet to be characterized. MCTs were predicted to have 12 transmembrane helices (TMs) with intracellular C- and N-termini and a large intracellular loop between TMs 6 and 7, and this was confirmed by labeling studies and proteolytic digestion. Site-directed mutagenesis has identified key residues required for catalysis and inhibitor binding and enabled the development of a molecular model of MCT1 in both inward and outward facing conformations. This suggests a likely mechanism for the translocation cycle. Although MCT family members are not themselves glycosylated, MCTs1-4 require association with a glycosylated ancillary protein, either basigin or embigin, for their correct translocation to the plasma membrane. These ancillary proteins have a single transmembrane domain and two to three extracellular immunoglobulin domains. They must remain closely associated with MCTs1-4 to maintain transporter activity. MCT1, MCT3, and MCT4 bind preferentially to basigin and MCT2 to embigin. The choice of binding partner does not affect substrate specificity or kinetics but can influence inhibitor specificity.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22131303     DOI: 10.1002/iub.573

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  236 in total

Review 1.  Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies.

Authors:  Kristofor A Olson; John C Schell; Jared Rutter
Journal:  Trends Biochem Sci       Date:  2016-02-10       Impact factor: 13.807

Review 2.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  Reducing monocarboxylate transporter MCT1 worsens experimental diabetic peripheral neuropathy.

Authors:  Mithilesh Kumar Jha; Xanthe H Ament; Fang Yang; Ying Liu; Michael J Polydefkis; Luc Pellerin; Brett M Morrison
Journal:  Exp Neurol       Date:  2020-07-25       Impact factor: 5.330

4.  In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.

Authors:  Xiaowen Guan; Mark A Bryniarski; Marilyn E Morris
Journal:  AAPS J       Date:  2018-11-05       Impact factor: 4.009

Review 5.  The role of HIF proteins in maintaining the metabolic health of the intervertebral disc.

Authors:  Elizabeth S Silagi; Ernestina Schipani; Irving M Shapiro; Makarand V Risbud
Journal:  Nat Rev Rheumatol       Date:  2021-06-03       Impact factor: 20.543

Review 6.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease.

Authors:  R S Jones; M E Morris
Journal:  Clin Pharmacol Ther       Date:  2016-08-22       Impact factor: 6.875

8.  Exercise-induced changes in tumour LDH-B and MCT1 expression are modulated by oestrogen-related receptor alpha in breast cancer-bearing BALB/c mice.

Authors:  Malihe Aveseh; Rohollah Nikooie; Mohsen Aminaie
Journal:  J Physiol       Date:  2015-05-18       Impact factor: 5.182

9.  Is higher lactate an indicator of tumor metastatic risk? A pilot MRS study using hyperpolarized (13)C-pyruvate.

Authors:  He N Xu; Stephen Kadlececk; Harrilla Profka; Jerry D Glickson; Rahim Rizi; Lin Z Li
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

10.  Hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane.

Authors:  Yi Rao; Seth Gammon; Niki M Zacharias; Tracy Liu; Travis Salzillo; Yuanxin Xi; Jing Wang; Pratip Bhattacharya; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.